# EpiBiologics

**Source:** https://geo.sig.ai/brands/epibiologics  
**Vertical:** BioTech  
**Subcategory:** Targeted Protein Degradation  
**Tier:** Emerging  
**Website:** epibiologics.com  
**Last Updated:** 2026-04-14

## Summary

Raised $107M Series B (Jan 2026) co-led by J&J Ventures and Google Ventures. EpiTAC targets membrane and secreted proteins — expanding degradation beyond intracellular-only. EPI-326 entering Phase 1 H1 2026.

## Company Overview

EpiBiologics develops EpiTAC — a targeted protein degradation platform designed to eliminate membrane and secreted proteins that existing degrader technologies cannot reach. The company raised $107 million in Series B financing in January 2026, co-led by Johnson & Johnson Ventures and Google Ventures, a rare investor pairing that brings both pharma development expertise and computational biology capabilities. The lead program, EPI-326 (an EGFR degrader for non-small cell lung cancer), is entering Phase 1 clinical trials in the first half of 2026.

Targeted protein degradation (TPD) — using molecular glues and PROTACs to hijack the cell's own protein disposal machinery — has become one of oncology's most active drug discovery fields. However, the majority of current degraders can only reach intracellular targets: the proteins inside the cell. EpiBiologics' EpiTAC platform extends degradation to membrane-bound receptors (including growth factor receptors and immune checkpoints) and secreted proteins in the extracellular space — dramatically broadening the target class that degradation approaches can address.

J&J Ventures' co-lead is particularly significant given Janssen's deep oncology portfolio and history of acquiring precision oncology assets: EpiBiologics' platform access to targets like EGFR — which has driven multiple Janssen-adjacent drug classes — signals potential strategic interest in both the technology and the clinical assets.

## Frequently Asked Questions

### What does EpiBiologics do?
Targeted protein degradation for membrane and secreted proteins — EpiTAC platform extends degradation beyond intracellular-only targets to include cell surface receptors and extracellular proteins.

### How much has EpiBiologics raised?
$107M Series B co-led by J&J Ventures and Google Ventures in January 2026. Lead program EPI-326 (EGFR, NSCLC) entering Phase 1 H1 2026.

### What is the EpiTAC advantage over existing degraders?
Current PROTACs and molecular glues only degrade intracellular proteins. EpiTAC reaches membrane receptors (EGFR, PD-L1) and secreted proteins — targets previously inaccessible to degradation.

### Why is J&J Ventures co-leading notable?
Janssen has a deep oncology portfolio and history of acquiring precision oncology assets. Co-leading the EpiBiologics Series B signals strategic interest in both the EpiTAC platform and its clinical pipeline.

### What is targeted protein degradation and how does EpiBiologics' EpiTAC work?
Targeted protein degradation uses bifunctional molecules that recruit cellular degradation machinery (the ubiquitin-proteasome system) to a target protein, tagging it for destruction rather than just inhibiting it. EpiBiologics' EpiTAC (Epigenetic Targeted Antibody Conjugate) conjugates a degrader warhead to an antibody — using the antibody for tumor-selective delivery and cell surface antigen binding, then triggering intracellular degradation of the target protein. This antibody-degrader conjugate approach combines ADC selectivity with protein degradation mechanism.

### What targets is EpiBiologics pursuing?
EpiBiologics focuses on oncology targets including epigenetic regulators (BET bromodomains, EZH2, HDAC complexes) that drive cancer cell survival through transcriptional reprogramming. Epigenetic proteins are biologically validated cancer targets but have proven difficult to drug with conventional inhibitors that block function transiently — degradation provides more durable suppression and may overcome resistance mechanisms seen with inhibitors. Specific lead programs are in early discovery optimization.

### What is the fundraising and investor profile for EpiBiologics?
EpiBiologics has raised significant early-stage venture funding with J&J (Johnson & Johnson) Innovation as a co-lead investor — notable strategic validation from one of the largest pharmaceutical companies with deep oncology and degrader expertise through its Janssen subsidiary. J&J's involvement suggests potential for partnership or licensing of successful EpiTAC programs into J&J's clinical pipeline.

### How does EpiTAC compare to conventional PROTACs and ADCs?
Conventional PROTACs (proteolysis-targeting chimeras) are small molecules that passively diffuse into all cells, lacking tumor selectivity and creating on-target toxicity in normal tissues. ADCs deliver cytotoxic payloads selectively to antigen-expressing tumor cells but don't degrade target proteins. EpiTAC combines ADC selectivity (antibody-mediated tumor targeting) with PROTAC-like mechanism (protein degradation) — potentially achieving both superior tumor selectivity and sustained target suppression that neither approach achieves alone.

## Tags

healthtech, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*